Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023
2023年11月21日 - 6:40AM
Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be
presenting at the Benchmark Company 12th Annual Discovery
One-on-One Investor Conference to be held Thursday December 7th,
2023 at the New York Athletic Club in New York City.
The conference offers emerging growth and
dynamic publicly traded companies access to institutional and
individual investors in a unique one-on-one format during which Jim
Green, Chairman and Chief Executive Officer, will be participating
in one-on-one meetings with investors and analysts throughout the
day. Joining him will be Jennifer Cote, the company’s Chief
Financial Officer and Treasurer.
To schedule a one-on-one meeting with Harvard
Bioscience, Inc., you may submit your request online via the link
provided upon registration. To register for the conference, please
visit
https://www.meetmax.com/sched/event_99181/investor_reg_new.html?attendee_role_id=INVESTOR
About Harvard
Bioscience
Harvard Bioscience, Inc. is a leading developer,
manufacturer and seller of technologies, products and services that
enable fundamental advances in life science applications, including
research, pharmaceutical and therapy discovery, bio-production and
preclinical testing for pharmaceutical and therapy development. Our
customers range from renowned academic institutions and government
laboratories to the world’s leading pharmaceutical, biotechnology
and contract research organizations. With operations in North
America, Europe, and China, we sell through a combination of direct
and distribution channels to customers around the world.
www.harvardbioscience.com.
Investor
Inquiries:Investors@harvardbioscience.com(508) 893-3120
About The Benchmark Company
The Benchmark Company is an institutionally
focused, research driven, sales trading and investment banking
firm. We were founded in 1988 and are headquartered in New York
City. Our focus is on fostering the long-term success of our
corporate clients through raising capital, providing strategic
advisory services, generating insightful research, and developing
institutional sponsorship by leveraging the firm’s sales, trading,
and equity research
capabilities.https://www.benchmarkcompany.com.
Harvard Bioscience (NASDAQ:HBIO)
過去 株価チャート
から 4 2024 まで 5 2024
Harvard Bioscience (NASDAQ:HBIO)
過去 株価チャート
から 5 2023 まで 5 2024